<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693677</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 61 - FUNGEMAX</org_study_id>
    <secondary_id>FFCD 1702</secondary_id>
    <secondary_id>2017-004309-41</secondary_id>
    <nct_id>NCT03693677</nct_id>
  </id_info>
  <brief_title>First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI</brief_title>
  <acronym>FUNGEMAX</acronym>
  <official_title>Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Europe, pancreatic cancer (PC) is the 7th most common cancer and the 5th leading cause of
      cancer death in Europe. Each year, the number of deaths due to prostate cancer is almost as
      high as the number of new cases diagnosed reflecting the poor prognosis associated with this
      disease. PC is insidious and is often diagnosed late. Despite advances in the management of
      other more common gastrointestinal cancers, the treatment of PC has had few benefits inherent
      in recent advances in digestive oncology. Gemcitabine has thus remained the reference
      treatment for more than 10 years.

      Recent studies have shown that gemcitabine/Nab-paclitaxel combination therapy is more
      effective in PC than gemcitabine-based therapy alone. In addition, multidrug therapy
      approaches (Irinotecan-5FU/LV) have also emerged to avoid the emergence of resistance to
      treatments while limiting toxicities. The recently developed Nal-IRI has also shown
      interesting efficacy in patients with metastatic PC previously treated with gemcitabine, with
      improved overall survival median and limited toxicity. Based on this information, the NAPOLI
      trial was conducted in patients with second line PC comparing the efficacy of Nal-IRI/5FU/LV
      or Nal-IRI and 5FU/LV alone; in this key study, the combination Nal-IRI/5FU/LV treatment was
      more effective than monotherapies (Nal-IRI or 5FU/LV alone).

      Based on all these data, a Phase II trial testing the standard of care
      gemcitabine/nab-paclitaxel vs Nal-IRI/5FU/LV vs Nal-IRI/5FU/LV 2-months sequential regimen
      followed by gemcitabine/nab-paclitaxel will be performed. This will allow us to i) know the
      tolerance and efficacy of Nal-IRI/5FU/LV in the first line of treatment, ii) test a new
      sequential strategy with Nal-IRI but also iii) compare our results in the experimental arms
      with one of the two world standard therapeutic regimens: gemcitabine + nab-Paclitaxel. All
      this in order to improve the management of patients with PC from the first line of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from
      cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new
      cases diagnosed each year, reflecting the poor prognosis typically associated with this
      disease. PC is insidious in onset and is often diagnosed late at the stage of metastatic
      spread. In spite of advances made in the management of other more common gastrointestinal
      cancers, the treatment of PC did take only a small advantage of recent progresses in
      gastrointestinal oncology and targeted therapies did not significantly modify its prognosis
      to date.

      Thus, for more than 10 years, gemcitabine has been the standard of care to treat metastatic
      PC. Recently, two positive phase III trials in metastatic PC were reported.

      First, the gemcitabine with nab-paclitaxel combination therapy was compared to gemcitabine
      alone in 861 randomized patients with metastatic PC. Results showed a significant improvement
      in response rate (RR), progression free survival (PFS) and overall survival (OS). Second, the
      results of the PRODIGE 4/ACCORD 11 trial testing the FOLFIRINOX regimen in metastatic PC
      patients, finally gave a hope showing a major improvement in PFS and OS as compared to
      gemcitabine. However, though manageable, the safety profiles of FOLFIRINOX and of gemcitabine
      plus nab-paclitaxel were less favourable than that of gemcitabine. These regimens were
      associated with a higher incidence of grade 3-4 neutropenia, febrile neutropenia,
      thrombocytopenia, diarrhoea, and grade 2-3 sensory neuropathy.

      Irinotecan has a stronger growth-inhibiting effect than cisplatin, mitomycin C and
      fluorouracil on cultured pancreatic adenocarcinoma cells. In most trials testing this
      molecule in PC patients, however, the response rates were low (&lt;10%) and survivals were poor.
      Intensive regimens with irinotecan and 5-FU have been developed in colorectal cancer patients
      to increase the anti-tumor effects of this combination therapy. From those, the FOLFIRI.3, in
      which the irinotecan is administered before and after a 5-FU 46h continuous infusion gave
      promising results. The investigator has tested this regimen in a phase II trial in advanced
      PC patients, with an objective RR of 37.5%, a median OS time of 12 months and acceptable
      tolerability. Considering these encouraging results the investigator has proposed a new
      approach to improve outcomes for patients with metastatic PC, using FOLFIRI.3 and gemcitabine
      alone, sequentially, to increase patient survival with a preserved quality of life (QOL).
      Indeed, some authors have reported that the administration of different patterns of
      sequential polychemotherapy was independently associated with OS in patients with PC and
      other gastrointestinal tumors such as metastatic colorectal cancer. Such strategies using
      drugs without cross-resistance sequentially may increase anti-tumor effects and limit
      cumulative and non-cumulative toxicities.

      The investigator thus performed a randomized multicentre phase II trial to assess this
      sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately in one arm and
      gemcitabine alone in the other arm, in patients with metastatic non pre-treated pancreatic
      adenocarcinoma. In this study the FIRGEM strategy seems to be an effective first line
      treatment option in good condition patients with metastatic PC. The primary endpoint was
      reached with a rate of PFS at 6 months of 44.9% in the FIRGEM arm while gemcitabine alone
      failed (25.7%). This good PFS rate at 6 months was maintained at 12 and 18 months (26.2% and
      18% respectively) though median PFS was 5.0 months. Moreover, an impressive objective
      response rate was observed in the FIRGEM arm (40%) as compared to the gemcitabine arm
      (11.4%). These results confirm those of the initial phase II trial evaluating the FOLFIRI.3
      regimen (37.5% objective response rate)(15) in PC patients and compare favourably with the
      31.6% and 23% reported in the two trials evaluating FOLFIRINOX and gemcitabine +
      nab-paclitaxel, respectively.

      Median overall survival was 11 months with FIRGEM versus 8.2 months with gemcitabine
      (HR:0.710 95% CI: 0.457-1.103). Here again the experimental arm gave good results, with
      median OS in the range of those reported with FOLFIRINOX (11.1 months). The safety profile of
      the FIRGEM strategy showed that hematological and GI toxicities were more important than with
      gemcitabine alone. Interestingly no limiting sensory neuropathy was observed with our
      treatment schedule and a significant increase in the time to definitive deterioration of the
      QoL was observed in the FIRGEM group as compared with the gemcitabine group. This effect was
      observed for all domains.

      Considering that nab-paclitaxel improves significantly patients outcome in metastatic PC when
      combined to gemcitabine, the addition of this drug to the FIRGEM strategy may be of
      particular interest. And the PRODIGE 37 trial tested this combination in a randomized phase
      II trial recently closed for inclusions. This trial allowed to fight the cancer with 4
      different drugs, without any cross resistance described between them, given sequentially in
      the first 4 months of treatment. Moreover, the &quot;resting period&quot; without nab-paclitaxel may
      delay significantly the occurrence of the cumulative neuropathy induced by this molecule and
      optimised its used with such a &quot;stop and go&quot; like strategy. Results are awaited for early
      2018.

      More recently a liposomal irinotecan has been developed and tested in pancreatic cancer
      patients, it comprises irinotecan free base encapsulated in liposome nanoparticles, which
      keep irinotecan into the circulation sheltered from conversion to its active metabolite
      (SN-38) longer and use local macrophage-mediated activation, which would increase and prolong
      intratumoral levels of both irinotecan and SN-38. In a phase II study of 40 patients with MPA
      previously treated with gemcitabine-based therapy, monotherapy with nal-IRI resulted in a
      median overall survival of 5.2 months, and a manageable toxicity profile. The NAPOLI-1 phase
      III trial was then conducted, comparing three arms of chemotherapy in patients previously
      treated with gemcitabine-based therapy: liposomal irinotecan (MM-398 or nal-IRI) alone or
      combined with 5FU and folinic acid, and 5FU and folinic acid alone. Combination of nal-IRI
      and 5FU/LV was more effective than 5FU alone or Nal-IRI alone (median OS of 6.1 vs. 4.2 and
      4.9 months respectively (HR: 0.67; p=0.012). Increased hematologic and GI toxicities were
      also seen in the Nal-IRI arms but were manageable. Nal-IRI plus 5FU and folinic acid extends
      survival in patients with metastatic pancreatic ductal adenocarcinoma who previously received
      gemcitabine-based therapy. In a setting where there is a paucity of second line treatment
      option, this combination is an important emerging treatment option for metastatic
      adenocarcinoma of the pancreas.

      Considering all these data, the investigator proposes to run a randomized phase II trial
      testing the standard continuous Gemcitabine + Nab-paclitaxel schedule vs Nal-IRI+5FU/LV vs
      Nal-IRI+5FU/LV for two months followed by Gemcitabine + Nab-paclitaxel for two months before
      starting again Nal-IRI. This will allow i) to generate efficacy and tolerability data on the
      Nal-IRI/5FU combination in the first line setting, ii) to test a new sequential strategy with
      Nal-IRI , in regards of the interesting results obtained in second and third line pancreatic
      cancer treatment, iii) to control our results in the experimental arms with one of the two
      first line worldwide standard regimen: Gemcitabine + Nab-paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression free survival at 6 months according to the RECIST 1.1 criteria</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time between the date of randomization and the date of the first radiological and/or clinical progression or the date of death (for whatever reason). Patients living without progression will be censured at date of last news. Progression is assessed by investigator and central review according to RECIST v1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival at 6 months (according to central review)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time between the date of randomization and the date of the first radiological and/or clinical progression or the date of death (for whatever reason). Patients living without progression will be censured at date of last news. Progression is assessed by investigator and central review according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response rate</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>BOR is defined as complete or partial response rate according to scans and RECIST v1.1 criteria over the entire treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the time between the date of randomization and the date of death (whatever the cause). Alive patients will be censured at date of last news.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Time to treatment failure is defined as the time between the date of randomization and the date of discontinuation of all protocol treatments (regardless of cause) or date last news for patients alive under treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Toxicities are evaluated according to NCI-CTC v4.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months
Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)
Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :
Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nal-IRI/5-FU/LV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nab-paclitaxel/Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)
Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :
Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Liposomal Injection</intervention_name>
    <description>Nal-IRI at 80 mg/m2 IV over 90 minutes</description>
    <arm_group_label>Nal-IRI/5-FU/LV</arm_group_label>
    <arm_group_label>Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively</arm_group_label>
    <other_name>Nal-IRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/LV</intervention_name>
    <description>5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.</description>
    <arm_group_label>Nal-IRI/5-FU/LV</arm_group_label>
    <arm_group_label>Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.</description>
    <arm_group_label>Nab-paclitaxel/Gemcitabine</arm_group_label>
    <arm_group_label>Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.</description>
    <arm_group_label>Nab-paclitaxel/Gemcitabine</arm_group_label>
    <arm_group_label>Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically or cytologically proven pancreatic adenocarcinoma (on primitive or
             metastatic lesion)

          -  Metastatic disease at a distance

          -  At least one measurable lesion according RECIST v1.1 criteria

          -  18 ≤ age ≤ 75 years

          -  Life expectancy &gt;12 weeks

          -  Performance status WHO &lt; 2

          -  No prior chemotherapy : adjuvant chemotherapy by gemcitabine +/- capecitabine is
             allowed if ended at least 12 months before the inclusion and adjuvant or neo-adjuvant
             FOLRIFINOX chemotherapy is allowed if ended at least 12 months prior the inclusion

          -  Pain well controlled before the inclusion of the patient

          -  ANC ≥ 1,500 cells/μL (without the use of hematopoietic growth factors); platelet count
             ≥ 100,000 cells/μL, hemoglobin ≥ 9 g/dL (blood transfusions is permitted for patients
             with hemoglobin levels below 9 g/dL)

          -  Adequate hepatic function as evidenced by: Serum total bilirubin within normal range
             for the institution (Serum bilirubin ≤ 1,5 UNL) Biliary drainage allowed for biliary
             obstruction.

          -  Albumin levels ≥ 3.0 g/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x
             ULN acceptable if liver metastases were present)

          -  Normal renal function test (creatinine clearance ≥ 50 ml/min)

          -  Normal ECG or ECG without any clinically significant findings

          -  Patient able to understand and sign an informed consent

          -  Females of child-bearing potential are required to test negative for pregnancy at the
             time of enrollment based on a urine or serum pregnancy test.

          -  Both male and female patients of reproductive potential were required to agree to use
             a reliable method of birth control, during the study and for 3 months following the
             last dose of study drug.

          -  Patient affiliated to social security

          -  Regular follow-up possible

        Exclusion Criteria:

          -  Uncontrolled brain or meningeal metastasis, or bone metastasis (no need of systematic
             CT scan)

          -  Prior radiation therapy (except if there is at least one measurable target outside
             irradiation area)

          -  Clinically significant gastrointestinal disorder including hepatic disorders,
             bleeding, inflammation, occlusion, or diarrhea &gt; Grade 1

          -  History of chronic inflammatory bowel disease

          -  Other types of pancreatic tumours, in particular endocrine or acinar cell tumours

          -  Ampulloma

          -  Gilbert's syndrome

          -  Presence of neuropathy &gt; grade 1 according to NCI-CTC

          -  History of any second malignancy in the last 5 years; subjects with prior history of
             in-situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other
             malignancies are eligible if they had been continuously disease free for at least 5
             years.

          -  Severe arterial thromboembolic events (myocardial infarction, unstable angina
             pectoris, stroke) less than 6 months before inclusion.

          -  NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled
             blood pressure.

          -  Known hypersensitivity to any of the drugs /constituents or non-liposomal irinotecan

          -  Any other medical or social condition deemed by the investigator to be likely to
             interfere with a patient's ability to sign informed consent, cooperate and participate
             in the study, or interferes with the interpretation of the results.

          -  Use of CYP3A4/UGT1A inducers/inhibitors

          -  Use of strong CYP2C8 inhibitors or inducers, or presence of any other
             contraindications for nab-paclitaxel or gemcitabine

          -  ILD presence

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Taieb, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP - Paris - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Gonzalez</last_name>
    <phone>+33 3.80.39.34.83</phone>
    <email>daniel.gonzalez@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique privée de l'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khadija KALAI</last_name>
      <phone>06 34 28 87 82</phone>
      <email>kalai_khadija@yahoo.fr ; khadija.kalai@cthe-amiens.fr</email>
    </contact>
    <contact_backup>
      <phone>03 60 12 76 78</phone>
    </contact_backup>
    <investigator>
      <last_name>Khadija KALAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole VITELLIUS</last_name>
      <phone>06 30 40 76 99</phone>
      <email>carole.vitellius@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <phone>02 41 35 62 90</phone>
    </contact_backup>
    <investigator>
      <last_name>Carole VITELLIUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François-Xavier CAROLI-BOSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique LUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume ROQUIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie BAIZE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne THIROT BIDAULT</last_name>
      <phone>06 81 96 85 57</phone>
      <email>a.t.bidault@gmail.com</email>
    </contact>
    <contact_backup>
      <phone>01 46 74 41 73</phone>
    </contact_backup>
    <investigator>
      <last_name>Anne THIROT BIDAULT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Auxerre</city>
        <zip>89000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure VILLING</last_name>
      <phone>03 86 48 47 65</phone>
      <email>alvilling@ch-auxerre.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Laure VILLING</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adina MARTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck AUDEMAR</last_name>
      <phone>05 59 44 37 22</phone>
      <email>faudemar@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Franck AUDEMAR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tam KHUONG HUU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne GUILNGAR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Félix GOUTORBE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence MARY</last_name>
      <phone>06 61 57 14 04</phone>
      <email>florence.mary@aphp.fr</email>
    </contact>
    <contact_backup>
      <phone>01 48 95 54 34</phone>
    </contact_backup>
    <investigator>
      <last_name>Florence MARY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre ROMPTEAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nils STEUER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc SABATE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Duchenne</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent BOURGEOIS</last_name>
      <phone>06 84 88 43 37</phone>
      <email>vincebourgeois@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>03 21 99 32 41</phone>
    </contact_backup>
    <investigator>
      <last_name>Vincent BOURGEOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire CAPELLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine BERNOU DRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Sainte Marie</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien MELIS</last_name>
      <phone>03 85 48 89 89</phone>
      <email>melisadrien@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Adrien MELIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline PETORIN</last_name>
      <phone>04 73 75 05 08</phone>
      <email>cpetorin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline PETORIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel BUC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis PEZET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès VIMAL-BAGUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68026</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BREYSACHER</last_name>
      <phone>06 82 04 27 96</phone>
      <email>gilles.breysacher@ch-colmar.fr</email>
    </contact>
    <contact_backup>
      <phone>03 89 12 51 23</phone>
    </contact_backup>
    <investigator>
      <last_name>Gilles BREYSACHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amalia TOPOLSCKI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion BOLLIET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samy LOUAFI</last_name>
      <phone>06 62 08 48 89</phone>
      <email>samy.louafi@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Samy LOUAFI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre GF Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila BENGRINE LEFEVRE</last_name>
      <phone>03 80 73 75 06</phone>
      <email>lbengrine@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Leila BENGRINE LEFEVRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François GHIRINGHELLI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie VINCENT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey HENNEQUIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine DROUILLARD</last_name>
      <phone>03 80 29 37 50</phone>
      <email>antoine.drouillard@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine DROUILLARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Côme LEPAGE, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain MANFREDI, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis JOUVE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice GAGNAIRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane DARUT-JOUVE</last_name>
      <phone>03 80 67 30 10</phone>
      <email>ariane.jouve@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Ariane DARUT-JOUVE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geneviève BOILLEAU-JOLIMOY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kheir Eddine BENMAMMAR</last_name>
      <phone>04 71 04 33 36</phone>
      <email>kheireddine.benmammar@ch-lepuy.fr</email>
    </contact>
    <investigator>
      <last_name>Kheir Eddine BENMAMMAR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Docteur Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62218</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne WATELLE</last_name>
      <phone>03 21 69 16 74</phone>
      <email>fwatelle@ch-lens.fr</email>
    </contact>
    <investigator>
      <last_name>Fabienne WATELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric THUILLIER</last_name>
      <phone>05 55 05 62 67</phone>
      <email>frederic.thuillier@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <phone>05 55 05 63 96</phone>
    </contact_backup>
    <investigator>
      <last_name>Frédéric THUILLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAVAU DENES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie LE BRUN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Longjumeau</city>
        <zip>91160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samy LOUAFI</last_name>
      <phone>06 62 08 48 89</phone>
      <email>samy.louafi@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Samy LOUAFI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joël EZENFIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique privée Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DESRAME</last_name>
      <phone>06 85 94 97 83</phone>
      <email>jerome.desrame@orange.fr</email>
    </contact>
    <contact_backup>
      <phone>04 37 53 87 26</phone>
    </contact_backup>
    <investigator>
      <last_name>Jérôme DESRAME</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léa CLAVEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal ARTRU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard LLEDO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves RINALDI</last_name>
      <phone>06 09 51 15 78</phone>
      <email>y.rinaldi@hopital-europeen.fr ; yrinaldi@wanadoo.fr</email>
    </contact>
    <contact_backup>
      <phone>04 13 42 75 35 (secrétariat)</phone>
    </contact_backup>
    <investigator>
      <last_name>Yves RINALDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas BARRIERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie GIGOUT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile JULIEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine GILABERT</last_name>
      <phone>06 61 95 59 02</phone>
      <email>gilabertm@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <phone>04 91 22 33 02</phone>
    </contact_backup>
    <investigator>
      <last_name>Marine GILABERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjorie FAURE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LOCHER</last_name>
      <phone>01 64 35 38 54</phone>
      <email>clocher@ghef.fr</email>
    </contact>
    <investigator>
      <last_name>Chirstophe LOCHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc PRIETO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence THOMAS MARQUES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Niort</city>
        <zip>79000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert ALEBA</last_name>
      <phone>05 49 78 36 79</phone>
      <email>albert.aleba@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Albert ALEBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre médical Oncogard</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent ALCARAZ</last_name>
      <phone>04 30 06 10 10</phone>
      <email>alcaraz.oncogard@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent ALCARAZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François PICAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques CRETIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Privé Sainte Marie</name>
      <address>
        <city>Osny</city>
        <zip>95520</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe SOYER</last_name>
      <phone>01 30 38 58 05</phone>
      <email>p.soyer@crom95.com</email>
    </contact>
    <investigator>
      <last_name>Philippe SOYER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abderrezak LADOUANI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine BRUNA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste BACHET</last_name>
      <phone>06 62 38 46 56</phone>
      <email>jean-baptiste.bachet@aphp.fr</email>
    </contact>
    <contact_backup>
      <phone>01 42 16 10 41</phone>
    </contact_backup>
    <investigator>
      <last_name>Jean-Baptiste BACHET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORIAT</last_name>
      <phone>06 60 65 52 79</phone>
      <email>romain.coriat@aphp.fr</email>
    </contact>
    <contact_backup>
      <phone>01 58 41 19 52</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne NETTER-COTI</last_name>
      <phone>06 89 67 91 54</phone>
      <email>jeanne.netter-coti@aphp.fr</email>
    </contact>
    <contact_backup>
      <phone>01 56 01 64 04</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeanne NETTER-COTI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier AMIOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David ANCEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien TAIEB, PR</last_name>
      <phone>06 60 55 22 35</phone>
      <email>jtaieb75@gmail.com</email>
    </contact>
    <contact_backup>
      <phone>01 56 09 35 56</phone>
    </contact_backup>
    <investigator>
      <last_name>Julien TAIEB, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LANDI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aziz ZAANAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline LEPERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clélia COUTZAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard AUCLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine PERKINS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Nicolas VAILLANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra LAPEYRE-PROST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire GALLOIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza KHEMISSA AKOUZ</last_name>
      <phone>06 14 25 25 44</phone>
      <email>faiza.khemissa@ch-perpignan.fr</email>
    </contact>
    <contact_backup>
      <phone>04 68 61 61 37</phone>
    </contact_backup>
    <investigator>
      <last_name>Faiza KHEMISSA AKOUZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Cario HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme MARTIN-BABAU</last_name>
      <phone>02 96 75 22 16</phone>
    </contact>
    <contact_backup>
      <last_name>Pierre-Luc ETIENNE</last_name>
      <phone>02 96 75 22 16</phone>
      <email>pl.etienne@cario-sante.fr ; pl.etienne@wanadoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jérôme MARTIN-BABAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Luc ETIENNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Claire HARDY BESSARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique BESSON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Jacques Puel</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MOSSER, MD</last_name>
      <phone>05 65 55 22 10</phone>
      <email>l.mosser@ch-rodez.fr</email>
    </contact>
    <investigator>
      <last_name>Guillermo REYEZ ORTEGA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique FABRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent MOSSER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric DI FIORE</last_name>
      <phone>06 82 23 33 89</phone>
      <email>frederic.difiore@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <phone>02 32 88 86 10</phone>
    </contact_backup>
    <investigator>
      <last_name>Frédéric DI FIORE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice GANGLOFF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David SEFRIOUI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélanie HASSINE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon CLAVEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre MICHEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>May MABRO</last_name>
      <phone>01 46 25 21 68</phone>
      <email>m.mabro@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>May MABRO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie GACHET-MASSON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolande NGUEFACK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony LOPEZ</last_name>
      <phone>06 78 56 21 57</phone>
      <email>anthony-lopez@hotmail.fr ; a.lopez@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <phone>03 83 15 76 92</phone>
    </contact_backup>
    <investigator>
      <last_name>Anthony LOPEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chloé MARECHAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastien DIRRENBERGEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clarac</name>
      <address>
        <city>Fort de France</city>
        <zip>97200</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie GROSSAT BERNADOU</last_name>
      <phone>05 96 59 26 01</phone>
      <email>nathalie.grossat-bernadou@chu-martinique.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie GROSSAT BERNADOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

